Andra AP fonden Increases Stake in United Therapeutics Corporation $UTHR

Andra AP fonden increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 33.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,904 shares of the biotechnology company’s stock after acquiring an additional 8,760 shares during the period. Andra AP fonden’s holdings in United Therapeutics were worth $18,912,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Security National Bank of SO Dak acquired a new position in shares of United Therapeutics during the second quarter worth about $179,000. Talon Private Wealth LLC increased its holdings in United Therapeutics by 31.8% in the second quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company’s stock valued at $3,659,000 after buying an additional 1,630 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in United Therapeutics by 4.4% in the second quarter. Sequoia Financial Advisors LLC now owns 2,530 shares of the biotechnology company’s stock valued at $1,371,000 after buying an additional 106 shares in the last quarter. Tidal Investments LLC lifted its holdings in United Therapeutics by 1.6% during the 2nd quarter. Tidal Investments LLC now owns 34,012 shares of the biotechnology company’s stock worth $18,429,000 after buying an additional 547 shares during the last quarter. Finally, Archford Capital Strategies LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth about $552,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently commented on UTHR. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Royal Bank Of Canada cut their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research report on Thursday, August 6th. Finally, Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $646.00.

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $494.79, for a total value of $4,700,505.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at $160,531,151.97. This represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $497.54, for a total transaction of $4,129,582.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $22,474,876.88. The trade was a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 355,553 shares of company stock worth $185,195,396. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

Shares of UTHR traded up $0.48 during trading hours on Tuesday, hitting $493.58. 107,976 shares of the company were exchanged, compared to its average volume of 514,729. United Therapeutics Corporation has a 52 week low of $409.07 and a 52 week high of $609.35. The firm’s 50 day moving average is $514.63 and its 200-day moving average is $540.46. The company has a market cap of $21.17 billion, a PE ratio of 17.67, a PEG ratio of 2.48 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the company posted $6.41 earnings per share. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. As a group, equities analysts forecast that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.